Your Kidneys Have Their Own Microbiome (And It Changes Everything)

This is Part 2 of the Microbiome & Kidney Stones series. Part 1 covered how gut bacteria degrade oxalate before it reaches your kidneys. This article covers what happens once oxalate arrives.

---

For over a century, medical students were taught a simple rule: urine is sterile. No bacteria live in the urinary tract of healthy people. If bacteria show up in a urine culture, you have an infection.

That rule is wrong.

Over the past decade — and accelerating dramatically in 2023 and 2024 — researchers have discovered that the urinary tract harbors its own microbial community, the urobiome. And in two landmark studies published in top-tier journals, scientists showed that the bacteria living in your urinary tract directly influence whether calcium oxalate crystals form, grow, and become kidney stones.

The implications for stone prevention are profound.

---

The Paradigm Shift: Urine Is Not Sterile

The "sterile urine" dogma was an artifact of technology. Traditional urine cultures were designed to detect infections — they grew bacteria on media optimized for pathogens like E. coli. If nothing grew, doctors called it "sterile."

But when researchers started using 16S rRNA gene sequencing — technology that detects bacterial DNA regardless of whether the organisms grow on a culture plate — they found bacteria everywhere. Healthy urine contains a diverse community of microorganisms, just at lower abundance than the gut.

This discovery spawned an entirely new field. By 2021, the research had matured enough that an international consortium called MICROCOSM was established specifically for microbiome research in urinary stone disease. Their standardization protocol was published in Nature Reviews Urology (Kachroo, Lange, Penniston, et al.), signaling that this wasn't fringe science — it was a field with enough critical mass to warrant formal consensus methods.

---

The Mahidol University Discovery

In September 2024, a team at Mahidol University in Bangkok published a study that would fundamentally change how we think about bacteria and kidney stones.

The paper: "The direct inhibitory effects of Lactobacillus acidophilus, a commensal urinary bacterium, on calcium oxalate stone development." Published in Microbiome (Impact Factor ~15), one of the most respected journals in the field. Authors: Noonin, Putpim, and Thongboonkerd.

They investigated two bacteria commonly found in the urinary tract:

• Lactobacillus acidophilus — abundant in healthy individuals
• Escherichia coli — associated with UTIs and stone formation

The results were striking:

L. acidophilus (the protector)

• Reduced new calcium oxalate crystal formation
• Reduced crystal growth (enlargement)
• Reduced crystal aggregation (clumping)
• Prevented crystals from adhering to kidney cell membranes

E. coli (the promoter)

• Increased crystal growth
• Increased crystal aggregation
• Had no significant crystal-degrading activity

The Surprise: It's Not About Eating Oxalate

Here's the counterintuitive finding that makes this study so important. The mechanism was not about bacteria degrading oxalate (the gut-based mechanism we covered in Part 1).

Neither bacteria significantly broke down oxalate crystals once formed. Instead, the effects were driven by surface protein structures:

• L. acidophilus uses its S-layer protein (a crystalline surface coating) to physically interfere with crystal formation and adhesion
• E. coli uses its flagella (whip-like appendages) to promote crystal growth and aggregation

When the researchers removed these surface proteins, the bacteria completely lost their ability to affect crystal formation. The mechanism is physical, not metabolic — these bacteria are interacting directly with calcium oxalate crystals through their outer structures.

This is an entirely different mechanism from the gut-based oxalate degradation by O. formigenes. Your body has two independent bacterial defense systems against kidney stones: one in the gut (metabolic degradation) and one in the urinary tract (physical crystal inhibition).

---

The Cleveland Clinic Breakthrough

Three months after the Mahidol study, in December 2024, a team at the Cleveland Clinic Lerner Research Institute published an even more dramatic finding in Nature Communications (Impact Factor ~16).

The paper: "Cefazolin shifts the kidney microbiota to promote a lithogenic environment." Authors: Agudelo, Chen, Mukherjee, Nguyen, Bruggeman, and Miller.

This was the first full characterization of the kidney microbiome meeting all three scientific criteria for a true microbiome: stability, consistency/reproducibility, and metabolic activity. Previous studies had detected bacteria in urine — this study proved that bacteria live in the kidneys themselves, in specific anatomical niches between glomeruli and tubules.

What They Found

The researchers examined how cefazolin — one of the most commonly used perioperative antibiotics (given before surgery to prevent infections) — affects the kidney's bacterial community.

The results:

1. Cefazolin selectively killed protective Lactobacillus species while promoting the proliferation of Enterobacteriaceae (the family that includes E. coli)
2. L. crispatus (a protective species) produced smaller, irregular crystals and appeared to reduce oxalate concentration in its environment
3. E. coli produced larger crystals with its flagella directly contacting crystal surfaces — physically promoting stone growth
4. When L. crispatus and E. coli were grown together, the result was very small crystal structures chemically distinct from kidney stones — the Lactobacillus blocked E. coli's stone-forming ability

---

Stone Formers vs. Healthy People: The Multi-Site Evidence

In November 2023, a team at Western University in Canada published what may be the most comprehensive comparison of stone formers and healthy controls to date.

The paper: "Multi-site microbiota alteration is a hallmark of kidney stone formation." Published in Microbiome. Authors: Al, Joris, Daisley, and colleagues (10 authors total).

They compared the gut, urinary, AND oral microbiota of 83 stone formers vs. 30 healthy controls. This was the first study to examine all three body sites simultaneously.

What They Found

Stone formers showed microbiota disturbances across all body sites, not just the urinary tract:

• Reduced microbial diversity — fewer different bacterial species
• Network collapse — breakdown of cooperative relationships between bacteria
• Functional replacement — health-associated pathways (vitamin production, butyrate biosynthesis) were displaced by virulence factors and antimicrobial resistance elements

Here's the provocative finding: the differences between stone formers and controls did NOT primarily involve oxalate metabolism genes. This challenges the assumption that urobiome effects on stones are mainly about oxalate degradation. Other mechanisms — inflammation, crystal adhesion, butyrate production — may matter as much or more.

The authors concluded that kidney stone treatment should consider "microbial functional restoration and the avoidance of aberrant modulators such as poor diet and antibiotics."

---

The Meta-Analysis: Consistent Across 5 Countries

In 2021, Kachroo and colleagues published a meta-analysis in mBio (American Society for Microbiology) that analyzed 6 clinical microbiome studies spanning 201 patient samples and 136 control samples from the USA, Canada, India, China, and Italy.

The consistent findings across all countries and research groups:

1. Lactobacillus in the urinary tract correlated with healthy individuals
2. Enterobacteriaceae (including E. coli) in the urinary tract correlated with stone disease
3. Prevotella in the gut correlated with healthy individuals
4. Stone formers showed reduced microbial diversity compared to healthy controls

These findings have since been confirmed by multiple additional studies, including a 2024 paper in Frontiers in Cellular and Infection Microbiology that was the first to show oxalate-degrading bacteria are present in the urinary tract but their degrading genes are significantly depleted in calcium oxalate stone formers.

---

How Established Is This Science?

Let's be transparent about where the field stands, because we believe in giving you the full picture — not just the exciting parts.

What's Strong

• The "urine is not sterile" paradigm shift is well-established and accepted by the scientific community
• The Lactobacillus-protective / E. coli-harmful pattern is consistent across multiple independent research groups in 6+ countries
• The antibiotic disruption mechanism is supported by both epidemiological data (Tasian 2018, N=285,000) and direct experimental evidence (Cleveland Clinic 2024)
• An international consortium (MICROCOSM) exists with consensus standards published in Nature Reviews Urology
• The American Urological Association published a review of this topic in May 2025

What's Still Early

• Most individual studies have small sample sizes — the meta-analysis covered only 337 total samples
• The mechanistic picture is more complex than "good bacteria vs. bad bacteria" — surface proteins, butyrate, inflammation, and electrostatic interactions all play roles
• No clinical application exists yet — we can't prescribe urinary probiotics or test your urobiome in a doctor's office
• We don't yet know how to restore a healthy urobiome once it's been disrupted

---

What This Means for You Right Now

While we can't yet manipulate the urobiome directly, this research reinforces several practical takeaways:

1. Question Prophylactic Antibiotics

If you're having kidney stone surgery, discuss the antibiotic protocol with your urologist. The Cleveland Clinic study showed that cefazolin specifically kills protective Lactobacillus while promoting stone-forming E. coli. This doesn't mean you should refuse antibiotics — infection is a real risk — but it's worth a conversation about alternatives and necessity.

2. Take UTI Prevention Seriously

Since E. coli promotes stone formation while Lactobacillus prevents it, avoiding UTIs isn't just about preventing infection — it may be about preventing stones. Adequate hydration, proper hygiene, and not holding urine for extended periods all support a healthy urobiome.

3. Stay Hydrated

Adequate hydration doesn't just dilute oxalate — it may help maintain a healthier urinary microbial environment. Concentrated urine creates conditions that favor pathogenic bacteria.

4. Track Your Diet

The gut-kidney axis and the urobiome are both real. But they're defense layers, not replacements for dietary management. Knowing your daily oxalate intake — which OxalateGuard makes easy to track — remains the most controllable variable in your kidney stone prevention strategy.

---

Coming Up: The Probiotic Question

Given everything we've covered in Part 1 (gut bacteria eat oxalate) and this article (urinary bacteria physically block crystal formation), the obvious question is: can you take a probiotic to prevent kidney stones?

The supplement industry says yes. The clinical trial evidence says something very different.

In Part 3: Can Probiotics Prevent Kidney Stones? The Honest Answer, we examine every major clinical trial — including the landmark study showing that diet reduced urinary oxalate by 36% while probiotics added zero additional benefit. It's the article no supplement company wants you to read.

---

Sources

1. Noonin C, Putpim A, Thongboonkerd V. The direct inhibitory effects of Lactobacillus acidophilus on calcium oxalate stone development. Microbiome. 2024;12(1):175.
2. Agudelo J, Chen X, Mukherjee SD, et al. Cefazolin shifts the kidney microbiota to promote a lithogenic environment. Nature Communications. 2024;15(1):10509.
3. Al KF, Joris BR, Daisley BA, et al. Multi-site microbiota alteration is a hallmark of kidney stone formation. Microbiome. 2023;11(1):263.
4. Kachroo N, et al. Meta-analysis of clinical microbiome studies in urolithiasis. mBio. 2021;12(4):e02007-21.
5. Kachroo N, Lange D, Penniston KL, et al. Standardization of microbiome studies for urolithiasis: an international consensus agreement. Nature Reviews Urology. 2021;18:303–311.
6. Patel SR, et al. The microbiome and urolithiasis: current advancements and future challenges. Current Urology Reports. 2022;23:47–56.
7. Agudelo J, Lange D, Tzou DT, Miller AW. Role of the urobiome and bacterial byproducts in urinary stone disease. AUA News. May 2025.
8. The urinary microbiota composition and functionality of calcium oxalate stone formers. Frontiers in Cellular and Infection Microbiology. 2024.
9. Update on the effect of the urinary microbiome on urolithiasis. Diagnostics. 2023;13(5):951.